Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181733 | 0.83 | NPC1 (0.46) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL31713594 | 0.82 | ALDH1A1 (0.40) | NPC1RAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL10181070 | 0.82 | ENPP2 (0.45) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL10180558 | 0.82 | PSIP1 (0.50) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL22518681 | 0.80 | NPC1 (0.43) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL2974299 | 0.80 | CA2 (0.53) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4733508 | 0.80 | LMNA (0.45) | NPC1RAB9ALMNAMAPK1CASP3 | |
| SCHEMBL66108 | 0.79 | ALDH1A1 (0.61) | NPC1RAB9ALMNAMAPK1SMN1; SMN2 | |
| SCHEMBL3041567 | 0.79 | ALDH1A1 (0.48) | LMNAMAPK1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1032223 | 0.78 | ALDH1A1 (0.40) | LMNASMN1; SMN2ALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-109503693-B | Process for synthesizing Aramchol by using cholic acid as raw material | 合肥工业大学 | 2021-04-06 | — | — | CN | disclosed |
| WO-2021039824-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | 国立大学法人 岡山大学 | 2021-03-04 | — | — | WO | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CHEMOCENTRYX INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CHEMOCENTRYX INC (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3263564-B1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| US-6492368-B1 | Benzamidine derivatives as factor XA inhibitors | MERCK PATENT GMBH (DE) | 2002-12-10 | — | — | US | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5728706-A | ENDOTHELIN ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0658548-B1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO (JP) | 1997-11-19 | — | — | EP | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| US-5589478-A | ENDOTHELIN ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0658548-A1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | EMG1, TRDMT1, BCDIN3D | NPC1 3564/4885RAB9A 2761/4885LMNA 3308/4885 |
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR1, CCR9, CCR8 | NPC1 872/4885RAB9A 2176/4885LMNA 3792/4885 |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CCR9, CCR1, CCR3 | NPC1 2659/4885RAB9A 2214/4885LMNA 4321/4885 |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | NPC1 4831/4885RAB9A 3431/4885LMNA 711/4885 |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | NPC1 2073/4885RAB9A 2077/4885LMNA 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.